Cargando…
Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus
[Image: see text] A series of novel 1,4-dioxane analogues of the muscarinic acetylcholine receptor (mAChR) antagonist 2 was synthesized and studied for their affinity at M(1)–M(5) mAChRs. The 6-cyclohexyl-6-phenyl derivative 3b, with a cis configuration between the CH(2)N(+)(CH(3))(3) chain in the 2...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007111/ https://www.ncbi.nlm.nih.gov/pubmed/32374602 http://dx.doi.org/10.1021/acs.jmedchem.9b02100 |
_version_ | 1783672431308701696 |
---|---|
author | Del Bello, Fabio Bonifazi, Alessandro Giorgioni, Gianfabio Piergentili, Alessandro Sabbieti, Maria Giovanna Agas, Dimitrios Dell’Aera, Marzia Matucci, Rosanna Górecki, Marcin Pescitelli, Gennaro Vistoli, Giulio Quaglia, Wilma |
author_facet | Del Bello, Fabio Bonifazi, Alessandro Giorgioni, Gianfabio Piergentili, Alessandro Sabbieti, Maria Giovanna Agas, Dimitrios Dell’Aera, Marzia Matucci, Rosanna Górecki, Marcin Pescitelli, Gennaro Vistoli, Giulio Quaglia, Wilma |
author_sort | Del Bello, Fabio |
collection | PubMed |
description | [Image: see text] A series of novel 1,4-dioxane analogues of the muscarinic acetylcholine receptor (mAChR) antagonist 2 was synthesized and studied for their affinity at M(1)–M(5) mAChRs. The 6-cyclohexyl-6-phenyl derivative 3b, with a cis configuration between the CH(2)N(+)(CH(3))(3) chain in the 2-position and the cyclohexyl moiety in the 6-position, showed pK(i) values for mAChRs higher than those of 2 and a selectivity profile analogous to that of the clinically approved drug oxybutynin. The study of the enantiomers of 3b and the corresponding tertiary amine 33b revealed that the eutomers are (2S,6S)-(−)-3b and (2S,6S)-(−)-33b, respectively. Docking simulations on the M(3) mAChR-resolved structure rationalized the experimental observations. The quaternary ammonium function, which should prevent the crossing of the blood–brain barrier, and the high M(3)/M(2) selectivity, which might limit cardiovascular side effects, make 3b a valuable starting point for the design of novel antagonists potentially useful in peripheral diseases in which M(3) receptors are involved. |
format | Online Article Text |
id | pubmed-8007111 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-80071112021-03-30 Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus Del Bello, Fabio Bonifazi, Alessandro Giorgioni, Gianfabio Piergentili, Alessandro Sabbieti, Maria Giovanna Agas, Dimitrios Dell’Aera, Marzia Matucci, Rosanna Górecki, Marcin Pescitelli, Gennaro Vistoli, Giulio Quaglia, Wilma J Med Chem [Image: see text] A series of novel 1,4-dioxane analogues of the muscarinic acetylcholine receptor (mAChR) antagonist 2 was synthesized and studied for their affinity at M(1)–M(5) mAChRs. The 6-cyclohexyl-6-phenyl derivative 3b, with a cis configuration between the CH(2)N(+)(CH(3))(3) chain in the 2-position and the cyclohexyl moiety in the 6-position, showed pK(i) values for mAChRs higher than those of 2 and a selectivity profile analogous to that of the clinically approved drug oxybutynin. The study of the enantiomers of 3b and the corresponding tertiary amine 33b revealed that the eutomers are (2S,6S)-(−)-3b and (2S,6S)-(−)-33b, respectively. Docking simulations on the M(3) mAChR-resolved structure rationalized the experimental observations. The quaternary ammonium function, which should prevent the crossing of the blood–brain barrier, and the high M(3)/M(2) selectivity, which might limit cardiovascular side effects, make 3b a valuable starting point for the design of novel antagonists potentially useful in peripheral diseases in which M(3) receptors are involved. American Chemical Society 2020-05-06 2020-06-11 /pmc/articles/PMC8007111/ /pubmed/32374602 http://dx.doi.org/10.1021/acs.jmedchem.9b02100 Text en Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Del Bello, Fabio Bonifazi, Alessandro Giorgioni, Gianfabio Piergentili, Alessandro Sabbieti, Maria Giovanna Agas, Dimitrios Dell’Aera, Marzia Matucci, Rosanna Górecki, Marcin Pescitelli, Gennaro Vistoli, Giulio Quaglia, Wilma Novel Potent Muscarinic Receptor Antagonists: Investigation on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions of the 1,4-Dioxane Nucleus |
title | Novel Potent Muscarinic
Receptor Antagonists: Investigation
on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions
of the 1,4-Dioxane Nucleus |
title_full | Novel Potent Muscarinic
Receptor Antagonists: Investigation
on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions
of the 1,4-Dioxane Nucleus |
title_fullStr | Novel Potent Muscarinic
Receptor Antagonists: Investigation
on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions
of the 1,4-Dioxane Nucleus |
title_full_unstemmed | Novel Potent Muscarinic
Receptor Antagonists: Investigation
on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions
of the 1,4-Dioxane Nucleus |
title_short | Novel Potent Muscarinic
Receptor Antagonists: Investigation
on the Nature of Lipophilic Substituents in the 5- and/or 6-Positions
of the 1,4-Dioxane Nucleus |
title_sort | novel potent muscarinic
receptor antagonists: investigation
on the nature of lipophilic substituents in the 5- and/or 6-positions
of the 1,4-dioxane nucleus |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007111/ https://www.ncbi.nlm.nih.gov/pubmed/32374602 http://dx.doi.org/10.1021/acs.jmedchem.9b02100 |
work_keys_str_mv | AT delbellofabio novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus AT bonifazialessandro novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus AT giorgionigianfabio novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus AT piergentilialessandro novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus AT sabbietimariagiovanna novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus AT agasdimitrios novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus AT dellaeramarzia novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus AT matuccirosanna novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus AT goreckimarcin novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus AT pescitelligennaro novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus AT vistoligiulio novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus AT quagliawilma novelpotentmuscarinicreceptorantagonistsinvestigationonthenatureoflipophilicsubstituentsinthe5andor6positionsofthe14dioxanenucleus |